Institutional
Catalio Capital Management, LP
The Brief · Catalio Capital Management, LP · Q1 2026
AI · grounded in 13F
Catalio Capital Management, LP closed its position in BridgeBio Oncology Therapeutics BBOT for a reduction of $31.4M. The fund established new positions in BridgeBio Pharma Inc BBIO for $32.1M, Definium Therapeutics Inc DFTX for $19.6M, and Incyte Corp INCY for $17.1M. Other significant exits included Eli Lilly & Co LLY at $27.9M and Johnson & Johnson JNJ at $25M. The fund also increased its share counts in UltraGenyx Pharmaceutical In RARE by 423.4% and Terns Pharmaceuticals Inc 430 by 198.7%.
Portfolio · Q1 2026
Top holdings
QoQ vs Q4 2025
| # | Ticker | Issuer | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|
| 1 | DNTH | DIANTHUS THERAPEUTICS INC | $47.0M | 9.82% | -93,264 | -14.3% |
| 2 | BBIO | BRIDGEBIO PHARMA INC | $32.1M | 6.70% | +432,014 | NEW |
| 3 | ASNDUSD | ASCENDIS PHARMA A/S | $29.5M | 6.17% | +9,846 | +8.3% |
| 4 | BMY | BRISTOL-MYERS SQUIBB CO | $25.5M | 5.33% | -227,172 | -35.1% |
| 5 | SNDX | SYNDAX PHARMACEUTICALS INC | $24.4M | 5.09% | -153,137 | -12.8% |
| 6 | GILD | GILEAD SCIENCES INC | $22.8M | 4.77% | -125,407 | -43.3% |
| 7 | 430 | TERNS PHARMACEUTICALS INC | $21.6M | 4.50% | +272,073 | +198.7% |
| 8 | DFTX | DEFINIUM THERAPEUTICS INC | $19.6M | 4.10% | +1,037,984 | NEW |
| 9 | SLNO | SOLENO THERAPEUTICS INC | $19.3M | 4.04% | +217,468 | +60.4% |
| 10 | BSX | BOSTON SCIENTIFIC CORP | $18.8M | 3.92% | -61,110 | -17.0% |
| 11 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $17.8M | 3.72% | +688,247 | +423.4% |
| 12 | INCY | INCYTE CORP | $17.1M | 3.58% | +182,101 | NEW |
| 13 | CYTK | CYTOKINETICS INC | $14.2M | 2.97% | -42,880 | -16.6% |
| 14 | NTRA | NATERA INC | $14.2M | 2.96% | +8,634 | +13.9% |
| 15 | CRVS | CORVUS PHARMACEUTICALS INC | $13.0M | 2.73% | +891,933 | NEW |
| 16 | GPCR | STRUCTURE THERAPEUTICS INC | $12.3M | 2.57% | +2,478 | +1.0% |
| 17 | MLYS | MINERALYS THERAPEUTICS INC | $11.9M | 2.48% | +107,192 | +32.3% |
| 18 | EW | EDWARDS LIFESCIENCES CORP | $11.6M | 2.42% | -42,441 | -22.7% |
| 19 | MANE | VERADERMICS INC | $11.0M | 2.29% | +173,582 | NEW |
| 20 | ADPT | ADAPTIVE BIOTECHNOLOGIES COR | $10.0M | 2.10% | -98,411 | -12.0% |
| 21 | HTFL | HEARTFLOW INC | $9.8M | 2.05% | +289,731 | +254.5% |
| 22 | KALV | KALVISTA PHARMACEUTICALS INC | $8.6M | 1.79% | +426,551 | NEW |
| 23 | QURE | UNIQURE NV | $8.0M | 1.68% | +202,771 | +70.3% |
| 24 | IRON | DISC MEDICINE INC | $7.9M | 1.64% | +12,551 | +11.4% |
| 25 | SEPN | SEPTERNA INC | $7.1M | 1.48% | — | HELD |
| 26 | ABVX | ABIVAX SA | $5.3M | 1.10% | -51,321 | -52.1% |
| 27 | DYN | DYNE THERAPEUTICS INC | $5.1M | 1.07% | -236,761 | -45.6% |
| 28 | ELDN | ELEDON PHARMACEUTICALS INC | $5.1M | 1.06% | +379,996 | +30.2% |
| 29 | KPTI | KARYOPHARM THERAPEUTICS INC | $5.0M | 1.04% | +754,725 | +527.8% |
| 30 | SUPN | SUPERNUS PHARMACEUTICALS | $3.2M | 0.67% | -195,446 | -75.9% |
| 31 | TARA | PROTARA THERAPEUTICS INC | $3.0M | 0.63% | -866,230 | -59.9% |
| 32 | PHAT | PHATHOM PHARMACEUTICALS INC | $2.8M | 0.58% | -451,229 | -64.6% |
| 33 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $2.7M | 0.56% | +83,554 | NEW |
| 34 | TYRA | TYRA BIOSCIENCES INC | $2.6M | 0.54% | +67,285 | NEW |
| 35 | IMCR | IMMUNOCORE HLDGS PLC | $2.5M | 0.53% | +84,352 | NEW |
| 36 | GUTS | FRACTYL HEALTH INC | $2.5M | 0.53% | — | HELD |
| 37 | HYPR | HYPERFINE INC | $1.4M | 0.30% | — | HELD |
| 38 | MGX | METAGENOMI THERAPEUTICS INC | $709K | 0.15% | — | HELD |
| 39 | ATAI | ATAIBECKLEY INC | $697K | 0.15% | +196,858 | NEW |
| 40 | SNSE | SENSEI BIOTHERAPEUTICS INC | $464K | 0.10% | — | HELD |
| 41 | OM | OUTSET MED INC | $454K | 0.09% | — | HELD |
| 42 | BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | — | — | -410,700 | EXITED |
| 43 | LLY | ELI LILLY & CO | — | — | -25,923 | EXITED |
| 44 | JNJ | JOHNSON & JOHNSON | — | — | -120,840 | EXITED |
| 45 | REGN | REGENERON PHARMACEUTICALS | — | — | -29,797 | EXITED |
| 46 | ISRG | INTUITIVE SURGICAL INC | — | — | -27,209 | EXITED |
| 47 | ADMA | ADMA BIOLOGICS INC | — | — | -564,461 | EXITED |
| 48 | ACLXGBX | ARCELLX INC | — | — | -156,109 | EXITED |
| 49 | OCUL | OCULAR THERAPEUTIX INC | — | — | -714,501 | EXITED |
| 50 | OLMA | OLEMA PHARMACEUTICALS INC | — | — | -267,058 | EXITED |
| 51 | GRAL | GRAIL INC | — | — | -30,313 | EXITED |
| 52 | FULC | FULCRUM THERAPEUTICS INC | — | — | -201,301 | EXITED |
| 53 | BLLN | BILLIONTOONE INC | — | — | -25,505 | EXITED |
| 54 | PVLA | PALVELLA THERAPEUTICS INC NE | — | — | -10,452 | EXITED |
| 55 | ATAI | ATAI BECKLEY NV | — | — | -196,858 | EXITED |
Source: SEC EDGAR · accession 0001958125-26-000003. 13F discloses long positions only — shorts, foreign equities, and options are excluded.